Why I see more upside ahead for AstraZeneca plc

I believe that AstraZeneca plc’s (LON: AZN) growth is only just getting started and there’s still plenty of potential for investors.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Year-to-date, shares in pharmaceutical giant AstraZeneca (LSE: AZN) have been on a roll. Since the beginning of the year, the stock has added 17% excluding dividends. 

After this performance, some analysts are starting to doubt whether the company can continue on its current trajectory. I believe that it can as new products are approved, and after years of stagnation, revenue growth begins to return. 

Improving outlook

Astra has staked its future on the development of immunotherapy treatments, which target cancer cells. So far, the group has had mixed success. Earlier in the year, the shares crashed when data from the eagerly awaited Mystic trial showed a combination medicine was no better than chemotherapy at keeping late-stage lung cancer at bay. However, two weeks after this disappointment, its Tagrisso drug was found to reduce the risk of progression or death by more than half, in patients with a particular mutation of lung cancer. 

Meanwhile, a treatment named Imfinzi improved progression-free survival by more than 11 months compared with the current standard therapy for sufferers of stage three cancer. 

These are not small breakthroughs, they are huge steps forward for the company and patients. They also show that the firm is heading in the right direction. Two steps ahead after one step back is, in my opinion, highly impressive. Combined, management estimates these treatments can produce $4bn of sales. 

Growth targets 

In 2014, Astra’s management promised investors that the company would hit $40bn in annual revenues by 2023. After several years of contraction, sales expansion was expected to start this year and continue to 2023, but so far, this growth has failed to materialise. 

Its last set of results in July showed sales down 10%, at constant currencies, in the first half of this year. City analysts are expecting earnings per share to decline by 12% for the full-year, which is hardly the most encouraging forecast. 

Nonetheless, analysts believe that next year, the fruits of Astra’s research work should begin to pay off. Earnings growth of just 1% is expected, hardly blowout growth but enough to stem the bleeding. This will be the only positive performance in seven years, and it should mark a turning point. 

Astra’s sales have been under pressure in recent years from multiple factors including pricing pressures and the expiry of exclusive manufacturing rights. While these factors are still proving to be headwinds, rising revenues from other sources are helping blunt the impact. I believe that this means, over the next few years, Astra should be able to return to growth. 

Time to buy?

Even though shares in Astra might look expensive today at a forward P/E of 18.1, they’re trading in line with the pharma sector median multiple (18.1). The shares support a dividend yield of 4%, which is almost double the sector median of 2%. 

This valuation, as well as the company’s outlook, leads me to conclude that as Astra’s growth picks up, the shares could head a lot higher as the market re-rates the business. With a dividend yield of 4%, investors are being paid to wait for this correction. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »